Rhumatologie

Efficacité et tolérance de l’infliximab pour le traitement de la spondylarthrite ankylosante (SPA) : suivi à deux ans en ouvert

Communications orales en sessions parallèles / Revue du Rhumatisme 71 (2004) 890-945 Gossec L, Breban M, Vignon E, Claudepierre P, Devauchelle-Pensec V, Wendling D, Lespessailles E, Euller-Ziegler M, Sibilia J, Perdriger A, Alexandre C, Dougados M.

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France
Rhumatologie

Impact of terminating reimbursement of symptomatic slow-acting drugs in osteoarthritis in France

THU0370 CLUSTER-RANDOMIZED PRAGMATIC CLINICAL TRIAL EVALUATING THE POTENTIAL BENEFIT OF A TIGHT-CONTROL AND TREAT-TO-TARGET STRATEGY IN AXIAL SPONDYLOARTHRITIS: THE RESULTS OF THE TICOSPA TRIAL
Rhumatologie

THU0370 CLUSTER-RANDOMIZED PRAGMATIC CLINICAL TRIAL EVALUATING THE POTENTIAL BENEFIT OF A TIGHT-CONTROL AND TREAT-TO-TARGET STRATEGY IN AXIAL SPONDYLOARTHRITIS: THE RESULTS OF THE TICOSPA TRIAL

Treat to target in axial spondyloarthritis: From its concept to its implementation
Rhumatologie

Treat to target in axial spondyloarthritis: From its concept to its implementation